Anti-PD-L1 antibody relieves T cell suppression by inhibiting the binding of PD-L1 to programmed cell death protein 1 (PD-1) and B7.1 (also known as CD80), which are receptors on effector T cells, and exerts antitumor effects in various types of cancer (2). Here, CD80 is linked to cancer.